Aquestive Therapeutics (AQST) Operating Margin: 2017-2025
Historic Operating Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -89.63%.
- Aquestive Therapeutics' Operating Margin fell 2841.00% to -89.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 424.07%, marking a year-over-year increase of 45990.00%. This contributed to the annual value of -3,052.68% for FY2024, which is 302282.00% down from last year.
- Per Aquestive Therapeutics' latest filing, its Operating Margin stood at -89.63% for Q3 2025, which was up 21.13% from -113.65% recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Operating Margin registered a high of 30.39% during Q4 2024, and its lowest value of -325.85% during Q2 2021.
- Over the past 3 years, Aquestive Therapeutics' median Operating Margin value was -41.36% (recorded in 2023), while the average stood at -59.21%.
- Examining YoY changes over the last 5 years, Aquestive Therapeutics' Operating Margin showed a top increase of 28,456bps in 2021 and a maximum decrease of 40,485bps in 2021.
- Quarterly analysis of 5 years shows Aquestive Therapeutics' Operating Margin stood at -105.33% in 2021, then surged by 504bps to -100.29% in 2022, then spiked by 7,067bps to -29.62% in 2023, then skyrocketed by 6,000bps to 30.39% in 2024, then tumbled by 2,841bps to -89.63% in 2025.
- Its Operating Margin stands at -89.63% for Q3 2025, versus -113.65% for Q2 2025 and -222.08% for Q1 2025.